These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND uPA
98 results:

  • 1. Association between circulating inflammatory proteins and benign prostatic disease: a Mendelian randomization study.
    Cao H; Shi C; Aihemaiti Z; Dai X; Wang F; Wang S
    Sci Rep; 2024 Oct; 14(1):23667. PubMed ID: 39390078
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Anti-Cancer Potential of Isoflavone-Enriched Fraction from Traditional Thai Fermented Soybean against Hela Cervical Cancer Cells.
    Sukhamwang A; Inthanon S; Dejkriengkraikul P; Semangoen T; Yodkeeree S
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273231
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma.
    Bønløkke ST; Fenger-Eriksen C; Ommen HB; Hvas AM
    Blood Adv; 2023 Nov; 7(22):7056-7066. PubMed ID: 37756519
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Studies on the changes of upa system in a co-culture model of bone marrow stromal cells-leukemia cells.
    Zhou L; Guo H; Jia F; Chen X; Zhang X; Dong S; Zhao L
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33146708
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Amentoflavone Induces Apoptosis and Reduces Expression of Anti-apoptotic and Metastasis-associated Proteins in Bladder Cancer.
    Chiang CH; Yeh CY; Chung JG; Chiang IT; Hsu FT
    Anticancer Res; 2019 Jul; 39(7):3641-3649. PubMed ID: 31262890
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Characteristics of fibrinolytic disorders in acute promyelocytic leukemia.
    Wang P; Zhang Y; Yang H; Hou W; Jin B; Hou J; Li H; Zhao H; Zhou J
    Hematology; 2018 Dec; 23(10):756-764. PubMed ID: 29724147
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The constitutive protease release by primary human acute myeloid leukemia cells.
    Honnemyr M; Bruserud Ø; Brenner AK
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):1985-1998. PubMed ID: 28631213
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral upaR-targeted chimera.
    Errico Provenzano A; Posteri R; Giansanti F; Angelucci F; Flavell SU; Flavell DJ; Fabbrini MS; Porro D; Ippoliti R; Ceriotti A; Branduardi P; Vago R
    Microb Cell Fact; 2016 Nov; 15(1):194. PubMed ID: 27842546
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Urokinase receptor and CXCR4 are regulated by common microRNAs in leukaemia cells.
    Alfano D; Gorrasi A; Li Santi A; Ricci P; Montuori N; Selleri C; Ragno P
    J Cell Mol Med; 2015 Sep; 19(9):2262-72. PubMed ID: 26082201
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. FLI1 expression is correlated with breast cancer cellular growth, migration, and invasion and altered gene expression.
    Scheiber MN; Watson PM; Rumboldt T; Stanley C; Wilson RC; Findlay VJ; Anderson PE; Watson DK
    Neoplasia; 2014 Oct; 16(10):801-13. PubMed ID: 25379017
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer.
    Shrimali D; Shanmugam MK; Kumar AP; Zhang J; Tan BK; Ahn KS; Sethi G
    Cancer Lett; 2013 Dec; 341(2):139-49. PubMed ID: 23962559
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Autocrine human growth hormone increases sensitivity of mammary carcinoma cell to arsenic trioxide-induced apoptosis.
    Zekri A; Ghaffari SH; Yousefi M; Ghanizadeh-Vesali S; Mojarrad M; Alimoghaddam K; Ghavamzadeh A
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):84-92. PubMed ID: 23851143
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer.
    Sroka IC; Sandoval CP; Chopra H; Gard JM; Pawar SC; Cress AE
    Mol Cancer Res; 2011 Oct; 9(10):1319-28. PubMed ID: 21824975
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (upaR) and their translation toward the clinic.
    Mazar AP; Ahn RW; O'Halloran TV
    Curr Pharm Des; 2011; 17(19):1970-8. PubMed ID: 21711234
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells.
    Dar A; Schajnovitz A; Lapid K; Kalinkovich A; Itkin T; Ludin A; Kao WM; Battista M; Tesio M; Kollet O; Cohen NN; Margalit R; Buss EC; Baleux F; Oishi S; Fujii N; Larochelle A; Dunbar CE; Broxmeyer HE; Frenette PS; Lapidot T
    Leukemia; 2011 Aug; 25(8):1286-1296. PubMed ID: 21494253
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Clinical and molecular features of papillary thyroid cancer in adolescents and young adults.
    Vriens MR; Moses W; Weng J; Peng M; Griffin A; Bleyer A; Pollock BH; Indelicato DJ; Hwang J; Kebebew E
    Cancer; 2011 Jan; 117(2):259-67. PubMed ID: 20824721
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.
    Carriero MV; Longanesi-Cattani I; Bifulco K; Maglio O; Lista L; Barbieri A; Votta G; Masucci MT; Arra C; Franco R; De Rosa M; Stoppelli MP; Pavone V
    Mol Cancer Ther; 2009 Sep; 8(9):2708-17. PubMed ID: 19706734
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
    Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA
    Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.
    Wang XD; Reeves K; Luo FR; Xu LA; Lee F; Clark E; Huang F
    Genome Biol; 2007; 8(11):R255. PubMed ID: 18047674
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. [Hemostatic disturbances in chronic myeloid leukemia].
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Bielis L
    Wiad Lek; 2007; 60(3-4):138-42. PubMed ID: 17726865
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.